Scott IU, et al. - In this investigation involving 236 participants (mean [SD] age, 68.5 (12.0) years), researchers analyzed outcomes 1 year after cessation of the Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2) treatment schedule. Follow-up included 117 candidates originally randomized to aflibercept and 119 candidates originally randomized to bevacizumab between September 17, 2014, and November 18, 2015. Once participants originally assigned to aflibercept were matched with those assigned to bevacizumab, no variations in Visual acuity letter score (VALS) or central subfield thickness (CST) results were found at month 24. Interpretation caution is needed due to the loss of follow-up. In both groups, when treatment was at the discretion of the investigator, VALS and CST improved during month 12 and then declined somewhat during the second year. This analysis suggests that in order to optimize results in eyes treated with anti-VEGF therapy, CRVO and HRVO require close monitoring and treatment over at least 2 years.